Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis
- 22 February 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 156 (1), 149-162
- https://doi.org/10.1007/s10549-016-3721-3
Abstract
Estrogen receptor (ER)-β has been discovered for decades; however, its prognostic value in breast cancer patients remains controversial. We aimed to evaluate the impact of ER-β expression on breast cancer survival. A systematic search of Medline, Embase, and Cochrane Library was performed to identify the association between ER-β expression and outcomes in early breast cancer patients. Random-effects meta-analysis was conducted to generate combined hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS). A total of 6769 patients for ER-β1, 2295 patients for ER-β2, and 2271 patients for ER-β5 from 21 studies were included. ER-β1 protein expression was correlated with both favorable 5-year DFS and OS (HR 0.690, 95 % CI 0.610–0.779; P < 0.001; HR 0.632, 95 % CI 0.533–0.749; P < 0.001), while ER-β1 mRNA had no significant association with DFS (HR 0.915, 95 % CI 0.581–1.440, P = 0.700). ER-β2 protein was associated with improved DFS (HR 0.799, 95 % CI 0.644–0.992; P = 0.042), but not OS (HR 0.958, 95 % CI 0.762–1.205; P = 0.712). ER-β5 protein was not significantly associated with DFS (HR 1.070, 95 % CI 0.810–1.410; P = 0.642). Subgroup analysis showed that higher ER-β1 expression was associated with better 5-year DFS in both ER-α positive and negative patients, but the positive association between ER-β1 expression and 5-year OS was only seen in ER-α positive patients. Wild-type ER-β (ER-β1) and its variant ER-β2 protein expressions are associated with better survival in early breast cancer patients. The prognostic significance of ER-β1 for DFS is independent of ER-α coexpression, whereas the impact on OS was only in ER-α positive breast cancer.Keywords
This publication has 45 references indexed in Scilit:
- Estrogen receptor beta in breast cancerMolecular and Cellular Endocrinology, 2013
- Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)Annals Of Oncology, 2013
- A bi-faceted role of estrogen receptor β in breast cancerEndocrine-Related Cancer, 2013
- Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine TherapyJournal of Breast Cancer, 2012
- A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective studyBreast Cancer Research, 2008
- Clinical Importance of Estrogen Receptor-β Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen TherapyJournal of Clinical Oncology, 2008
- The genome landscape of ERα- and ERβ-binding DNA regionsProceedings of the National Academy of Sciences, 2008
- Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective studyBMC Cancer, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Cloning of a novel receptor expressed in rat prostate and ovary.Proceedings of the National Academy of Sciences, 1996